Suppr超能文献

托莫西汀和哌甲酯对注意缺陷多动障碍儿童睡眠的影响。

Effects of atomoxetine and methylphenidate on sleep in children with ADHD.

作者信息

Sangal R Bart, Owens Judith, Allen Albert J, Sutton Virginia, Schuh Kory, Kelsey Douglas

机构信息

Clinical Neurophysiology Services, PC, Troy, MI, USA.

出版信息

Sleep. 2006 Dec;29(12):1573-85. doi: 10.1093/sleep/29.12.1573.

Abstract

STUDY OBJECTIVES

This study compared the effects of atomoxetine and methylphenidate on the sleep of children with attention-deficit/hyperactivity disorder (ADHD). This study also compared the efficacy of these medications for treating ADHD in these children.

DESIGN

Randomized, double-blind, crossover trial.

SETTING

Two sleep disorders centers in the United States; 1 in a private-practice setting and 1 in a hospital setting.

PATIENTS

85 children diagnosed with ADHD.

INTERVENTIONS

Twice-daily atomoxetine and thrice-daily methylphenidate, each for approximately 7 weeks.

MEASUREMENTS AND RESULTS

Relative to baseline, the actigraphy data indicated that methylphenidate increased sleep-onset latency significantly more than did atomoxetine (39.2 vs 12.1 minutes, p < .001). These results were consistent with the polysomnography data. Child diaries indicated that it was easier to get up in the morning, it took less time to fall asleep, and the children slept better with atomoxetine, compared with methylphenidate. Parents reported that it was less difficult getting their children up and getting them ready in the morning and that the children were less irritable, had less difficulty getting ready for bed, and had less difficulty falling asleep with atomoxetine, compared with methylphenidate. There were no significant differences between medications using the main measures of efficacy for ADHD treatment. Atomoxetine was superior on some secondary ADHD treatment-efficacy measures, based on parent reports. The only significant differences in treatment-emergent adverse events were greater incidence of decreased appetite and greater incidence of insomnia with methylphenidate.

CONCLUSIONS

Patients receiving twice-daily atomoxetine had shorter sleep-onset latencies, relative to thrice-daily methylphenidate, based on objective actigraphy and polysomnography data. Although both medications decreased nighttime awakenings, the decrease was greater for methylphenidate.

摘要

研究目的

本研究比较了托莫西汀和哌甲酯对注意力缺陷多动障碍(ADHD)儿童睡眠的影响。本研究还比较了这些药物治疗这些儿童ADHD的疗效。

设计

随机、双盲、交叉试验。

地点

美国的两个睡眠障碍中心;一个在私人诊所,一个在医院。

患者

85名被诊断为ADHD的儿童。

干预措施

每日两次服用托莫西汀和每日三次服用哌甲酯,各约7周。

测量与结果

相对于基线,活动记录仪数据表明,哌甲酯使入睡潜伏期显著延长的程度超过托莫西汀(39.2对12.1分钟,p<0.001)。这些结果与多导睡眠图数据一致。儿童日记表明,与哌甲酯相比,服用托莫西汀时早晨更容易起床,入睡所需时间更短,睡眠质量更好。家长报告称,与哌甲酯相比,服用托莫西汀时叫孩子起床并让他们准备好出门的难度较小,孩子不那么烦躁,准备睡觉的难度较小,入睡也更容易。在ADHD治疗的主要疗效指标方面,两种药物之间没有显著差异。根据家长报告,托莫西汀在一些ADHD治疗次要疗效指标上更具优势。治疗中出现的不良事件的唯一显著差异是哌甲酯导致食欲下降的发生率更高和失眠的发生率更高。

结论

根据客观的活动记录仪和多导睡眠图数据,每日两次服用托莫西汀的患者相对于每日三次服用哌甲酯的患者入睡潜伏期更短。虽然两种药物都减少了夜间觉醒,但哌甲酯的减少幅度更大。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验